Glioblastoma Multiforme (astrocytoma grade IV) is the most frequently occurring malignant brain tumor. It is also the most malignant, with a median survival of only 12 months. Despite of the optimization of current standard treatment, which consists surgery combined with radiation- and chemotherapy. It is revealed that glioblastomas are a heterogeneous group of tumors at a molecular level, which makes it challenging to find a medically angle of treatment. Based on this there is a need to develop a new classification of glioblastomas, with the objective to develop a personalized treatment for this group of patients. There must also simultaneously be developed biomarkers and other diagnostic methods that can predict for response to various treatments. Here, various mutations of significance and their association to survival and response with standard treatment will be featured. Furthermore, it is outlined potentially promising new therapeutic methods with different molecular point of attack. In the end are various diagnostic methods described, including neuroimaging and other noninvasive methods.